Fibroblast growth factor 21 is required for the therapeutic effects of Lactobacillus rhamnosus GG against fructose-induced fatty liver in mice

Cuiqing Zhao, Li Liu, Qi Liu, Fengyuan Li, Lihua Zhang, Fenxia Zhu, Tuo Shao, Shirish Barve, Yiping Chen, Xiaokun Li, Craig J. McClain, Wenke FengMolecular 2019 · DOI

Abstract

LGG administration increases hepatic FGF21 expression and serum ADPN concentration, resulting in a reduced ChREBP activation through dihydrosphingosine-1-phosphate-mediated PP2A deactivation, and subsequently reversed fructose-induced NAFLD. Thus, our data suggest that FGF21 is required for the beneficial effects of LGG in reversal of fructose-induced NAFLD.
BibTeX
@inproceedings{zhao2019fibroblast,
  author = {Cuiqing Zhao and Li Liu and Qi Liu and Fengyuan Li and Lihua Zhang and Fenxia Zhu and Tuo Shao and Shirish Barve and Yiping Chen and Xiaokun Li and Craig J. McClain and Wenke Feng},
  title = {{Fibroblast growth factor 21 is required for the therapeutic effects of Lactobacillus rhamnosus GG against fructose-induced fatty liver in mice}},
  booktitle = {Molecular},
  year = {2019},
  doi = {10.1016/j.molmet.2019.08.020},
}

Loading related content...

Figure